CD274 and neoplasm: Although PD-L1 expression on tumor cells has been utilized in numerous clinical trials and has approved clinical indications as a potential predictive biomarker for ICI response, the accuracy and reliability of FDA-approved PD-L1 expression assays and the application of PD-L1 as a predictive marker have raised many concerns [39,41].